Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) (ABNL-MARRO)

compound in combination with ASTX727, an oral drug combining fixed doses of the DNA methyltransferase inhibitor (DNMTi) decitabine and the cytidine deaminase inhibitor E7727, also known as cedazuridine in

  • 0 views
  • 15 Jul, 2022
  • 1 location
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Multicenter, open-label study of various ASTX727 LD doses and schedules to assess safety, pharmacodynamics, pharmacokinetics, and hematologic response in subjects with International Prognostic

blood transfusion
decitabine
  • 40 views
  • 21 Jul, 2022
  • 35 locations
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

This is a Phase 1b, multicenter, open-label, pharmacokinetic (PK), and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose

leukemia
hematologic malignancy
lymphoma
cancer
direct bilirubin
  • 0 views
  • 25 Jul, 2022
  • 6 locations
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

This is a Phase 1b, multicenter, open-label, PK, and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine

leukemia
cancer
acute promyelocytic leukemia
hematologic malignancy
lymphoma
  • 0 views
  • 27 Jul, 2022
  • 8 locations
Lutathera and ASTX727 in Neuroendocrine Tumours (LANTana)

Patients entered into the study will receive ASTX727 orally up to 3 to 8 days prior to receiving Lutathera treatment to determine whether pre-treatment with ASTX727 results in re-expression of

  • 0 views
  • 20 Jul, 2022
  • 1 location
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.

  • 3 views
  • 13 Feb, 2022
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

The purpose of this study is to see whether the study drug ASTX727 is an effective treatment for people who have MPNST with a PCR2 mutation. ASTX727 is a combination of two drugs

  • 0 views
  • 15 Mar, 2022
  • 7 locations
Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

This phase II trial studies the possible benefits of venetoclax and ASTX727 in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment

  • 0 views
  • 26 Apr, 2022
  • 1 location
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to

  • 0 views
  • 27 Jul, 2022
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

The Phase 1 portion of this study is a single-arm, open-label, multicenter, non-randomized interventional study to evaluate the pharmacokinetic (PK) interaction, safety, and efficacy of ASTX727

induction chemotherapy
carbon monoxide
ejection fraction
decitabine
venetoclax
  • 0 views
  • 08 Aug, 2022
  • 15 locations